Advertisement
Table 1 Clinical characteristics before ASCT
| Characteristic | N | Per cent | OS 100 days | NRM 100 days | ||
|---|---|---|---|---|---|---|
| 433 | 100% | OR (95% CI) | p | OR (95% CI) | p | |
| Years of age, median (range; p10; p90): 56 (18–72; 35; 67) | ||||||
| 18–45 | 105 | 24 | 0.28 | 0.29 | ||
| 46–55 | 98 | 23 | ||||
| 56–65 | 165 | 38 | ||||
| 66–72 | 65 | 15 | ||||
| Female sex | 151 | 35 | 0.39 | 0.26 | ||
| ASCT year | ||||||
| 1994–1999 | 42 | 10 | 0.43 | 0.25 | ||
| 2000–2009 | 161 | 37 | ||||
| 2010–2016 | 230 | 53 | ||||
| Indication for ASCT | ||||||
| Planned upfront | 155 | 36 | 0.054 | 0.053 | ||
| Relapsed/refractory | 278 | 64 | ||||
| Years since lymphoma diagnosis, median (range): 1.2 (0.2–22.6) | 0.45 | 0.40 | ||||
| Number of prior lines of therapy | ||||||
| 1 | 161 | 40 | 0.16 | 0.20 | ||
| 2 | 201 | 50 | ||||
| ≥ 3 | 44 | 11 | ||||
| Days between date of last chemotherapy and date of ASCT, median (range; p10; p90): 35 (20–415; 27; 53) | ||||||
| < 28 | 54 | 14 | 0.79 | 0.48 | ||
| 28–34 | 135 | 34 | ||||
| 35–41 | 113 | 28 | ||||
| 42–55 | 63 | 16 | ||||
| ≥ 56 | 33 | 8 | ||||
| Prior rituximab | 263 | 61 | 0.069 | 0.12 | ||
| Prior fludarabine | 26 | 6 | 0.91 | 0.72 | ||
| ASCT in poor remission | 70 | 16 | 0.32 | 0.90 | ||
| Harvested CD34+ cells/kg, median (range; p10; p90): 6.2 (1.0–48.0; 3.4; 13.7) | ||||||
| 1.0–3.9 million | 59 | 14 | 2.0 (0.7–6.2) | 0.040 | 3.4 (1.0–11.4) | 0.040 |
| 4.0–4.9 million | 50 | 12 | 4.2 (1.6–11.2) | 5.2 (1.6–16.9) | ||
| 5.0–9.9 million | 228 | 54 | 1 | 1 | ||
| 10.0–48.0 million | 82 | 20 | 1.4 (0.5–4.3) | 1.9 (0.5–6.9) | ||
| < 5 vs ≥ 5 million | 3.1 (1.5–6.5) | 0.003 | 4.0 (1.7–9.4) | 0.001 | ||
| Stem cell source | ||||||
| Peripheral blood | 424 | 98 | 1 | 0.008 | 1 | 0.002 |
| Bone marrow | 9 | 2 | 7.1 (1.7–29.8) | 9.4 (2.2–40.3) | ||
| Leukocytes per nL, median (range; p10, p90): 4.1 (1.0–25.9; 2.2; 7.2) | ||||||
| Normal or high (≥ 3.5) | 271 | 65 | 0.062 | 0.059 | ||
| Neutrophils per nL, median (range; p10; p90): 2.4 (< 0.2–45.0; 1.0; 5.1) | ||||||
| Normal or high (≥ 1.5) | 246 | 76 | 0.13 | 0.26 | ||
| Lymphocytes per nL, median (range; p10; p90): 0.8 (0.3–8.3; 0.4; 1.9) | ||||||
| Normal or high (≥ 1.0) | 65 | 37 | 0.65 | 0.40 | ||
| Platelets per nL, median (range; p10; p90): 199 (7–1395; 105; 363) | ||||||
| Low (< 150) | 114 | 27 | 3.2 (1.5–6.6) | 0.002 | 4.9 (2.1–11.7) | 0.0003 |
| Haemoglobin in g/L, median (range; p10; p90): 105 (75–150; 91; 123) | ||||||
| Low (< 120) | 364 | 87 | 0.25 | 0.45 | ||
| Creatinine in multiples of UNL, median (range; p10; p90): 0.74 (0.29–1.90; 0.58; 1.02) | ||||||
| Elevated (≥ UNL) | 50 | 12 | 2.8 (1.2–6.8) | 0.018 | 4.1 (1.6–10.1) | 0.002 |
| Albumin in g/L, median (range; p10; p90): 37 (14–44; 32; 41) | ||||||
| Low (< 36) | 102 | 26 | 2.6 (1.2–5.7) | 0.016 | 3.2 (1.3–7.9) | 0.013 |
| C-reactive protein in mg/L, median (range; p10; p90): 2 (0–169; 0; 20) | ||||||
| < 3 | 160 | 50 | 1 | 0.0006 | 1 | 0.0013 |
| 3–9 | 83 | 26 | 5.6 (1.4–21.6) | 6.3 (1.2–31.9) | ||
| ≥ 10 | 75 | 24 | 9.0 (2.4–33.3) | 11.0 (2.3–52.5) | ||
| Conditioning | ||||||
| BEAM | 403 | 93 | 0.61 | 0.80 | ||
| BEAC | 22 | 5 | ||||
| BCNU-thiotepa | 7 | 2 | ||||
| Cy-TBI | 1 | 0 | ||||
| Given dose of CD34+ cells/kg, median (range; p10; p90): 6.0 (1.0–48.0; 3.4; 11.4) | ||||||
| 1.0–3.9 million | 61 | 15 | 0.087 | 0.071 | ||
| 4.0–4.9 million | 58 | 14 | ||||
| 5.0–9.9 million | 233 | 56 | ||||
| 10.0–48.0 million | 66 | 16 | ||||
| Tandem-treatment after ASCT | 45 | 10 | 1.0 | 1.0 | ||
| Local irradiation | 22 | 5 | ||||
| Splenectomy | 2 | 0 | ||||
| Temozolomide maintenance | 18 | 4 | ||||
| Allogeneic SCT | 3 | 1 | ||||
